Recce Pharmaceuticals Ltd. RCE
ASX · Australia · Health Technology
AUD 0.3250+0.02 (+4.84%)
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Two of healthcare’s most pressing challenges - the growing prevalence of diabetes and rising antibiotic resistance - are converging in diabetic foot infections, where slow-healing wounds can develop into serious infections, hospitalisation and amputation. The International Diabetes Federation...
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has secured Australian Human Research Ethics Committee (HREC) approval for a further protocol amendment to its pivotal Phase 3 trial of RECCE® 327 Topical Gel (R327G), adding a 208-patient active-controlled study arm in diabetic foot infections...
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) is positioned to benefit from a new five-year, US$66.9 billion US Government strategy aimed at strengthening national defences against pandemics, antimicrobial resistance and other major biological threats. The strategy identifies broad-spectrum...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.